secwatch.observer — SEC 8-K summary
======================================

Issuer:     enVVeno Medical Corp (NVNO)
CIK:        0001661053
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-022440
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enVVeno loses FDA appeal for VenoValve PMA; shifts focus to enVVe device
------------------------------------------------------------------------

- Unfavorable FDA appeal upheld not-approvable letter for VenoValve (received Aug 19, 2025).
- Company to redirect resources to next-gen transcatheter valve enVVe, ready for human testing.
- Cash and investments totaled $31.5M at Q3 end; quarterly burn $4-5M funds operations into 2027.
- No approved treatments exist for severe deep CVI from valvular incompetence, affecting up to 3.5M US patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661053/000149315225022440/0001493152-25-022440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661053/000149315225022440/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer